The Food and Drug Administration (FDA) had granted Shire’s Biologics License Application (BLA) for lanadelumab (SHP643) priority review.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
U.S. drugmaker Gilead Sciences has announced that it will use Sangamo Therapeutics gene-editing technology to develop cancer treatments in a deal worth potentially $3 billion to Sangamo.
AstraZeneca has secured approval for one of its key new lung cancer drugs, cementing the medicine’s potential to become a blockbuster treatment.
Novartis is gearing up to auction its U.S. generic pill business, a unit that has struggled amid fierce competition, a move pointing to the idea that biosimilars will be the end of ‘big pharma’.
Roche has announced that it intends to purchase the rest of the U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.
Biological drugs are complex molecules made in living cells, and they have changed medicine in the past two decades, offering rich choices for companies making almost identical copies as patents expire.
The Food and Drug Administration (FDA) has been busy this week. Their most recent approval is for Johnson & Johnson’s Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.
Britain’s Oxford BioMedica has a lot to be happy about right now, since its win in a second $100 million contract to supply gene therapy material from Bioverativ.